Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
168.6 USD | +1.89% | +7.84% | +8.78% |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
Jun. 06 | AbbVie's ovarian cancer therapy succeeds in mid-stage trial | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.78% | 292B | |
+43.64% | 749B | |
+39.42% | 605B | |
-6.58% | 351B | |
+19.72% | 328B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.03% | 167B | |
+6.13% | 165B | |
+1.39% | 123B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Barclays Adjusts Price Target on AbbVie to $185 From $175, Maintains Overweight Rating